Immunokinase-directed therapeutics have been one of the highest returning drug classes for biotech investors in recent years. Drugs that inhibit the JAK family, BTK, Syk, and PI3Kd have all generated impressive clinical validation in B- and T-cell diseases, and created lots of excitement on both the deal-making and stock market fronts.